Tarsus nabs key data in hunt to repurpose dog drug as cure for eye parasite
Eight months after their $101 million IPO, Tarsus Pharmaceuticals say they’ve cleared the first of two trials needed to prove to their FDA that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
